Article

Development and Optimization of Naproxen Sodium Controlled Release Tablets: QbD Approach

Atul Phatak1★, Dhanashri Joshi1, Mahesh Bhadgale2, Pravin Chaudhari1★ Corresponding author

  1. 1Department of Pharmaceutics, PES’s Modern College of Pharmacy, Sector 21, Yamunanagar, Nigdi, Pune, Maharashtra, INDIA.
  2. 2Department of Formulation Research and Development, Callidus Research Labs, Chakan Industrial Area, Nighoje, Pune, Maharashtra, INDIA.

CORRESPONDENCE

Atul Phatak

Department of Pharmaceutics, PES’s Modern College of Pharmacy, Sector 21, Yamunanagar, Nigdi, Pune, Maharashtra, INDIA.

atulapin@yahoo.com

Received: 13-08-2019; Revised: 27-09-2019; Accepted: 26-02-2020.

Volume 54, Issue 2S · pp. s108–s116 · PUBLISHED 2020 · DOI: 10.5530/ijper.54.2s.67

View on IJPER original site ↗

ABSTRACT

Objectives: The aim of present study was to formulate and optimize Multi-unit Naproxen Sodium controlled release tablet by QbD approach. Controlled release dosage form for naproxen sodium was selected to reduce dosing frequency and gastrointestinal side effects of drug. Methods: Naproxen Sodium CR tablets were prepared by using wet granulation method by employing Quality by Design (QbD). This tablet was made by a mixture of a granulate having an immediate release with a granulate having a controlled release, in terms of the active ingredient. Eudragit RSPO and RLPO polymers were used to control the drug release. Optimization of tablet formulation was done using 23 factorial design to study the effect of concentration of Eudragit RSPO, Eudragit RLPO polymers and concentration of disintegrating agent i.e. crospovidone on disintegration time and f2 factor of drug released. Tablets were evaluated for thickness, hardness, friability, assay and drug release. Results: Optimized formulation shows controlled drug release profile upto 14 hrs. with disintegration time of 88 min. Conclusion: It was concluded that tablet formulation of Naproxen Sodium CR tablets employing QbD leads to a single dose per day in the management of rheumatoid arthritis and also concluded that Eudragit RLPO and Eudragit RSPO polymers can be successfully used to controlled drug release profile of tablet.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Phatak, A., Joshi, D., Bhadgale, M., & Chaudhari, P. (2020). Development and Optimization of Naproxen Sodium Controlled Release Tablets: QbD Approach. Indian Journal of Pharmaceutical Education and Research, 54(2S), s108–s116. https://doi.org/10.5530/ijper.54.2s.67